Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020.
Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).
The enhanced single cell analysis with protein expression (ESCAPE) platform represents a suite of technologies developed by Proteona using DNA barcoded antibodies. It empowers us to obtain both proteomic and genomic information from the same single cells.
With the power of the ESCAPE platform, you can now phenotype cells based on protein panels measuring >50 protein markers, while simultaneously measuring all potential mRNAs in each cell. ESCAPE provides the greatest insights possible into clinically important samples.
Based in Singapore with additional operations in the US and Germany, Proteona has been assisting clinical laboratories around the world with their ESCAPE kit, sample-to-answer services, and bioinformatics support.
Chief Executive Officer
Andreas is a serial entrepreneur and a successful biotech CEO in both Asia and Europe. He previously built up the venture capital backed proteomics company AYOXXA with a 45 people team in Singapore, Cologne and Boston raising more than 40 Million USD. He currently serves as a board member, advisor and mentor for several biotech companies, including Venneos and Aescuvest.
Jonathan has brought multiple research and diagnostic technologies from conception to market. As a scientist at Natera, he developed multiple genetic diagnostic tests and implemented them into the clinical service lab. He has also subsequently led four products from concept to market at NuGen Technologies (products created under the Ovation™ line) and his own company, Alaneo Genetics.
Shawn has been involved with many large-scale genome projects ranging from the sequencing of the Fugu genome to chemical genomic profiling. He has published widely in the area of bioinformatics and next-generation sequencing and has worked closely with Dr. Sydney Brenner to establish the Molecular Engineering Laboratory and managing a multidisciplinary team of 20 scientists.
Dr. Goldstein is the former SVP/CTO Greater Asia of Beckton Dickson, and serves as Board member for innovative start-up companies. Dr. Goldstein’s leadership resulted in many new commercialised medical devices and diagnostic products whose annual sales total in the billions. He has championed new innovation sources that include start-up incubators in the US and Singapore.
Dr. Yeo is a Professor of Cellular and Molecular Medicine at the University of California,San Diego (UCSD). He has authored more than 160 peer-reviewed publications and books. Dr. Yeo is a co-founder of biotech companies which includes Locana, Eclipse Bioinnovations, Enzerna and Proteona. He serves or had served on the scientific advisory boards of various start-ups.
Proteona is the leader in single cell multi-omics and to revolutionize immuno-oncology and immune profiling. We are constantly challenging new boundaries of technologies. You can join us to help make a difference in science, diagnosis, and medicine.